Robert,
I ask the same thing a few hrs ago and got no response. Thank god I am not losing it. Perhaps Yahoo made an error.
Capt. Ron
I saw the same thing in DLJ Direct and also in MS Investor.
Biolase Technology, Inc. Reports 1998 First Quarter Results
May 21, 1998 08:17 AM
SAN CLEMENTE, Calif., May 21 /PRNewswire/ -- BIOLASE TECHNOLOGY, INC. BLTI , an international provider of advanced medical, dental and surgical products, today announced its first quarter results for the period ended March 31, 1998.
Sales for the first quarter of 1998 were $262,530, as compared to $134,405 for the same period last year, an increase of 95%. The Company reported a quarterly loss of $829,111, or $0.06 per share for the first quarter of 1998, versus a quarterly loss of $767,734, or $0.06 a share for the same period last year.
"In the past few months, we realized several significant accomplishments," stated Donald A. La Point, President, and CEO of BIOLASE. "In the beginning of the first quarter, we submitted clinical data to the FDA to support clearance of Millennium(TM) for hard tissue; we finalized the design of the LaserBrush(TM); we added key operational personnel to our senior management team; and we commenced shipment of the Millennium(TM) to both Canada and Italy." La Point added, "Subsequent to the quarter end, we were granted a U.S. patent for our HydroKinetic(TM) technology incorporated within our Millennium(TM) systems; we executed a letter of intent to acquire the assets of Laser Skin Toner, Inc., a company which owns a proprietary, non-invasive laser technology for use in the aesthetic and skin rejuvenation markets; we executed a $10.7 million distribution agreement with a major Asian distributor; and we completed a $3,900,000 capital infusion to fund the Company's future growth."
BIOLASE Technology, Inc. manufactures and markets advanced cosmetic, medical, dental and surgical products including its HydroKinetic(TM) surgical cutting systems and other traditional laser systems, and develops specialized biomaterials for dentistry and other medical specialties. The Company's products incorporate new patented and patent-pending technologies that achieve unique results.
The matters discussed in this news release include forward looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
BIOLASE TECHNOLOGY, INC.
Summary Consolidated Financial Information
Three Months Ended
March 31, March 31,
Dorine |
